HERPES SIMPLEX VIRUS TYPE 2 IN PREGNANCY IN UGANDA: EFFECT OF ACYCLOVIR-PROPHYLAXIS FROM 28-36 WEEKS ON OBSTETRIC ADVERSE OUTCOMES.

TO DETERMINE THE EFFECT OF ACYCLOVIR FROM 28 -36 WEEKS ON RISK OF PRE-PROM AND ADVERSE OBSTETRIC OUTCOMES INCLUDING SHEDDING IN NEW MULAGO HOSPITAL.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201311000558197

Enrollment

200

Registered

2013-06-07

Start date

2013-10-15

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Herpes Simplex type 2, Prelabour rupture of membranes

Interventions

acyclovir from 28 weeks

plain placebo from 28 weeks to 36 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: -HSV-2 sero-positive pregnant women -Any parity -At 28 weeks of gestation -18 years and above -Have consented to the study.

Exclusion criteria

Exclusion criteria: -Those involved in other intervention studies that may confound our findings -already have outcome of interest

Design outcomes

Primary

Measure	Time frame
occurrence preterm prelabour rupture of membranes/preterm delivery	—

Secondary

Measure	Time frame
¿ Maternal pelvic infections ¿ Genital shedding. ¿ Fetal Apgar score, admission into neonatal special care unit, fetal death, low birth weight Adverse drug events	—

Countries

Uganda

Contacts

Public ContactDan Kaye

Assoc Prof Dept OBS /GYN, SOM, MakCHS

dankkaye@yahoo.com256 772 587952

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026